Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATH-1020 · 1 trial · 1 indication
Safety and tolerability of single or multiple ascending doses of ATH-1020 as measured by vital signs and clinical laboratory measurements.
| Arm | Type | Description |
|---|---|---|
| ATH-1020 | EXPERIMENTAL | ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5). |
| Placebo | PLACEBO_COMPARATOR | Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo. |
| Name | Type | Description |
|---|---|---|
| ATH-1020 | DRUG | ATH-1020 in oral capsule form |
| Placebo | DRUG | Placebo in oral capsule form |
Inclusion Criteria: All Subjects 1. Body mass index (BMI) of ≥ 18.0 and ≤ 32.0 kg/m2 at Screening, with minimum weight of 60 kg. 2. Subjects in generally good health per the investigator's discretion. 3. Male subjects and their partners must be willing to comply with the contraceptive requirements...
ATH-1020 is an investigational small molecule developed by LeonaBio, Inc. It is a Phase 1 clinical-stage candidate studied in healthy adult volunteers in the United States. No approved indication has been disclosed for ATH-1020.
ATH-1020 targets HGF, also known as hepatocyte growth factor, a protein. HGF is a signaling protein, and ATH-1020 is a small molecule designed to act on this target. The specific therapeutic use being pursued has not been disclosed.
ATH-1020 is being developed by LeonaBio, Inc., which trades under the ticker LONA. LeonaBio is the sponsor of the clinical program for ATH-1020.
ATH-1020 is in Phase 1 development. It is an investigational drug and is not approved by the FDA. The Phase 1 program has completed one trial, and no trials are currently active.
ATH-1020 has been studied in one completed Phase 1 trial, NCT05169671, titled Safety, Tolerability, and Pharmacokinetics Study of ATH-1020. The trial enrolled 32 healthy volunteers in the United States and was randomized, double-blind, and placebo-controlled.